Trial Profile
A Multicentre Randomised Clinical Trial of Intravitreal Bevacizumab (Avastin) Versus Intravitreal Dexamethasone (Ozurdex) for Persistent Diabetic Macular Oedema
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jan 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Dexamethasone (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms BEVORDEX
- 01 Jan 2023 Results of five years outcomes assessing long-term efficacy and safety published in the British Journal of Ophthalmology
- 02 Jun 2015 Status changed from active, no longer recruiting to completed. as reported by ClinicalTrials.gov.
- 29 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.